Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy
- 4 May 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 13 (12), 975-986
- https://doi.org/10.1007/s00520-005-0828-1
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- PCN8 COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY IN THE UKValue in Health, 2004
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Renal Failure with the Use of Zoledronic AcidThe New England Journal of Medicine, 2003
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003
- Effectiveness and cost of bisphosphonate therapy in tumor bone diseaseCancer, 2003
- Bone metastases: Approaches to managementSeminars in Oncology, 2001
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trialsSeminars in Oncology, 2001
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- Subgroup and cost‐benefit analysis of the Finnish multicentre trial of clodronate in multiple myelomaBritish Journal of Haematology, 1994